Endothelial dysfunction in diabetes: From mechanisms to therapeutic targets

Current Medicinal Chemistry

Volumn 16, Issue 1, 2009, Pages 94-112

  Potenza, Maria Assunta ^a   Gagliardi, Sara ^a   Nacci, Carmela ^a   Carratu, Maria Rosario ^a   Montagnani, Monica ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Diabetes; Endothelial dysfunction; Nitric oxide; Reactive oxygen species; Therapeutic strategies

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT INHIBITOR; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIOXIDANT; ASCORBIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; FATTY ACID; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSIGLITAZONE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN INHIBITOR; ANTILIPEMIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME STRUCTURE; FLUID RETENTION; GLUCOSE OXIDATION; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; MICROALBUMINURIA; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; VASODILATATION; WEIGHT GAIN; ANIMAL; DIABETIC ANGIOPATHY; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTILIPEMIC AGENTS; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 61949439551     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787002853     Document Type: Review

References (265)

1. Vane, J.R.; Anggard, E.E.; Botting, R.M. Regulatory functions of the vascular endothelium. N. Engl. J. Med., 1990, 323, 27-36.
2. Luscher, T.F.; Barton, M. Biology of the endothelium. Clin. Cardiol., 1997, 20(11 Suppl 2), II-3-10.
3. Mann, G.E.; Yudilevich, D.L.; Sobrevia, L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol. Rev., 2003, 83, 183-252.
4. Furchgott, R.F.; Vanhoutte, P.M. Endothelium-derived relaxing and contracting factors. FASEB J., 1989, 3, 2007-18
5. Furchgott, R.F.; Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, 373-6.
6. Griffith, O.W.; Stuehr, D.J. Nitric oxide synthases: Properties and catalytic mechanism. Annu. Rev. Physiol., 1995, 57, 707-36.
7. Govers, R.; Rabelink, T.J. Cellular regulation of endothelial nitric oxide synthase. Am. J. Physiol. Renal. Physiol., 2001, 280, F193-206.
8. Fleming, I.; Bauersachs, J.; Busse, R. Calcium-dependent and calcium-independent activation of the endothelial NO synthase. J. Vasc. Res., 1997, 34, 165-74.
9. Garcia-Cardena, G.; Fan, R.; Stern, D.F.; Liu, J.; Sessa, W.C. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J. Biol. Chem., 1996, 271, 27237-40.
10. Michell, B.J.; Chen, Z.; Tiganis, T.; Stapleton, D.; Katsis, F.; Power, D.A.; Sim, A.T.; Kemp, B.E. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem., 2001, 276, 17625-8.
11. Michel, J.B.; Michel, T. The role of palmitoyl-protein thioesterase in the palmitoylation of endothelial nitric oxide synthase. FEBS Lett., 1997, 405, 356-62.
12. Garcia-Cardena, G.; Fan, R.; Shah, V.; Sorrentino, R.; Cirino, G.; Papapetropoulos, A.; Sessa, W.C. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature, 1998, 392, 821-4.
13. Michel, J.B.; Feron, O.; Sacks, D.; Michel, T. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+- calmodulin and caveolin. J. Biol. Chem., 1997, 272, 15583-6.
14. Gratton, J.P.; Bernatchez, P.; Sessa, W.C. Caveolae and caveolins in the cardiovascular system. Circ. Res., 2004, 94, 1408-17.
15. Zeng, G.; Quon, M.J. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest., 1996, 98, 894-8.
16. Montagnani, M.; Chen, H.; Barr, V.A.; Quon, M.J. Insulin-stimulated activation of eNOS is Independent of Ca++ but Requires phosphorylation by Akt at Ser1179. J. Biol. Chem., 2001, 276, 30392-8.
17. Boo, Y.C.; Sorescu, G.; Boyd, N.; Shiojima, I.; Walsh, K.; Du, J.; Jo, H. Shear stress stimulates phosphorylation of eNOS at Ser1179 by Akt- independent mechanisms - Role of Protein Kinase A. J. Biol. Chem., 2001, 29, 29.
18. Chen, H.; Montagnani, M.; Funahashi, T.; Shimomura, I.; Quon, M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem., 2003, 278, 45021-6.
19. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A.M. Activation of nitric oxide synthase in endothelial cells by Akt- dependent phosphorylation. Nature, 1999, 399, 601-5.
20. Fulton, D.; Gratton, J.P.; McCabe, T.J.; Fontana, J.; Fujio, Y.; Walsh, K.; Franke, T.F.; Papapetropoulos, A.; Sessa, W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 1999, 399, 597-601.
21. Munzel, T.; Feil, R.; Mulsch, A.; Lohmann, S.M.; Hofmann, F.; Walter, U. Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase [corrected]. Circulation, 2003, 108, 2172-83.
22. Moncada, S.; Higgs, A. The L-arginine-nitric oxide pathway. N. Engl. J. Med., 1993, 329, 2002-12.
23. Sasaki, N.; Sato, T.; Ohler, A.; O'Rourke, B.; Marban, E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation, 2000, 101, 439-45.
24. Landry, D.W.; Oliver, J.A. The pathogenesis of vasodilatory shock. N. Engl. J. Med., 2001, 345, 588-95.
25. Davis, M.J.; Hill, M.A. Signaling mechanisms underlying the vascular myogenic response. Physiol. Rev., 1999, 79, 387-423.
26. Schafer, A.; Wiesmann, F.; Neubauer, S.; Eigenthaler, M.; Bauersachs, J.; Channon, K.M. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation, 2004, 109, 1819-22
27. Sarkar, R.; Meinberg, E.G.; Stanley, J.C.; Gordon, D.; Webb, R.C. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ. Res., 1996, 78, 225-30.
28. Stamler, J.S.; Lamas, S.; Fang, F.C. Nitrosylation. The prototypic redox-based signaling mechanism. Cell, 2001, 106, 675-83.
29. Ghosh, S.; Karin, M. Missing pieces in the NF-kappaB puzzle. Cell, 2002, 109 Suppl, S81-96.
30. Moncada, S.; Erusalimsky, J.D. Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat. Rev. Mol. Cell Biol., 2002, 3, 214-20.
31. Halcox, J.P.; Narayanan, S.; Cramer-Joyce, L.; Mincemoyer, R.; Quyyumi, A.A. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am. J. Physiol. Heart Circ. Physiol., 2001, 280, H2470-7.
32. Mombouli, J.V.; Vanhoutte, P.M. Endothelium-derived hyperpolarizing factor(s): Updating the unknown. Trends Pharmacol. Sci., 1997, 18, 252-6.
33. Busse, R.; Edwards, G.; Feletou, M.; Fleming, I.; Vanhoutte, P.M.; Weston, A.H. EDHF: Bringing the concepts together. Trends Pharmacol. Sci., 2002, 23, 374-80.
34. Moncada, S.; Higgs, E.A.; Vane, J.R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet, 1977, 1, 18-20.
35. Nacci, C.; Tarquinio, M.; De Benedictis, L.; Mauro, A.; Zigrino, A.; Carratu, M.R.; Quon, M.J.; Montagnani, M. Endothelial Dysfunction in Mice with Streptozotocin-induced Type 1 Diabetes is Opposed by Compensatory Overexpression of COX-2 in the Vasculature. Endocrinology, 2008.
36. Mukherjee, D.; Nissen, S.E.; Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-9.
37. Graham, D.J.; Campen, D.; Hui, R.; Spence, M.; Cheetham, C.; Levy, G.; Shoor, S.; Ray, W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet, 2005, 365, 475-81.
38. Davidge, S.T. Prostaglandin H synthase and vascular function. Circ. Res., 2001, 89, 650-60.
39. Lever, A.F.; Lyall, F.; Morton, J.J.;Folkow, B. Angiotensin II, vascular structure and blood pressure. Kidney Int. Suppl., 1992, 37, S51-5.
40. Kerr, S.; Brosnan, M.J.; McIntyre, M.; Reid, J.L.; Dominiczak, A.F.; Hamilton, C.A. Superoxide anion production is increased in a model of genetic hypertension: Role of the endothelium. Hypertension, 1999, 33, 1353-8.
41. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1988, 332, 411-5.
42. Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanishi, S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature, 1990, 348, 730-2.
43. Sakurai, T.; Yanagisawa, M.; Takuwa, Y.; Miyazaki, H.; Kimura, S.; Goto, K.; Masaki, T. Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature, 1990, 348, 732-5.
44. Marasciulo, F.L.; Montagnani, M.; Potenza, M.A. Endothelin-1: The yin and yang on vascular function. Curr. Med. Chem., 2006, 13, 1655-65.
45. Muldoon, L.L.; Rodland, K.D.; Forsythe, M.L.; Magun, B.E. Stimulation of phosphatidylinositol hydrolysis, diacylglycerol release, and gene expression in response to endothelin, a potent new agonist for fibroblasts and smooth muscle cells. J. Biol. Chem., 1989, 264, 8529-36.
46. Schiffrin, E.L. Endothelin and endothelin antagonists in hypertension. J. Hypertens., 1998, 16, 1891-5.
47. de Nucci, G.; Gryglewski, R.J.; Warner, T.D.; Vane, J.R. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc. Natl. Acad. Sci. U. S. A., 1988, 85, 2334-8
48. Hirata, Y.; Emori, T.; Eguchi, S.; Kanno, K.; Imai, T.; Ohta, K.; Marumo, F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J. Clin. Invest., 1993, 91, 1367-73.
49. Malek, A.; Izumo, S. Physiological fluid shear stress causes down-regulation of endothelin-1 mRNA in bovine aortic endothelium. Am. J. Physiol., 1992, 263, C389-96.
50. Barton, M.; Shaw, S.; d'Uscio, L.V.; Moreau, P.; Luscher, T.F. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation. Biochem. Biophys. Res. Commun., 1997, 238, 861-5.
51. Ito, H.; Hirata, Y.; Adachi, S.; Tanaka, M.; Tsujino, M.; Koike, A.; Nogami, A.; Murumo, F.; Hiroe, M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin IIinduced hypertrophy in cultured rat cardiomyocytes. J. Clin. Invest., 1993, 92, 398-403.
52. Matsuura, A.; Yamochi, W.; Hirata, K.; Kawashima, S.; Yokoyama, M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension, 1998, 32, 89-95.
53. Corder, R.; Carrier, M.; Khan, N.; Klemm, P.; Vane, J.R. Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J. Cardiovasc. Pharmacol., 1995, 26 Suppl 3, S56-8.
54. Quehenberger, P.; Exner, M.; Sunder-Plassmann, R.; Ruzicka, K.; Bieglmayer, C.; Endler, G.; Muellner, C.; Speiser, W.; Wagner, O. Leptin induces endothelin-1 in endothelial cells in vitro. Circ. Res., 2002, 90, 711-8.
55. Lteif, A.A.; Han, K.; Mather, K.J. Obesity, insulin resistance, and the metabolic syndrome: Determinants of endothelial dysfunction in whites and blacks. Circulation, 2005, 112, 32-8.
56. Kim, J.A.; Koh, K.K.; Quon, M.J. The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 889-91.
57. Montagnani, M.; Quon, M.J. Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension. Diabetes Obes. Metab., 2000, 2, 285-92.
58. Muniyappa, R.; Montagnani, M.; Koh, K.K.; Quon, M.J. Cardiovascular actions of insulin. Endocr. Rev., 2007, 28, 463-91.
59. Baron, A.D.; Steinberg, H.O.; Chaker, H.; Leaming, R.; Johnson, A.; Brechtel, G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J. Clin. Invest., 1995, 96, 786-92.
60. Zeng, G.; Nystrom, F.H.; Ravichandran, L.V.; Cong, L.N.; Kirby, M.; Mostowski, H.; Quon, M.J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation, 2000, 101, 1539-45.
61. Montagnani, M.; Golovchenko, I.; Kim, I.; Koh, G.Y.; Goalstone, M.L.; Mundhekar, A.N.; Johansen, M.; Kucik, D.F.; Quon, M.J.; Draznin, B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J. Biol. Chem., 2002, 277, 1794-9.
62. Potenza, M.A.; Marasciulo, F.L.; Chieppa, D.M.; Brigiani, G.S.; Formoso, G.; Quon, M.J.; Montagnani, M. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, H813-22.
63. Eringa, E.C.; Stehouwer, C.D.; van Nieuw Amerongen, G.P.; Ouwehand, L.; Westerhof, N.; Sipkema, P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am. J. Physiol. Heart Circ. Physiol., 2004, 287, H2043-8.
64. Cardillo, C.; Nambi, S.S.; Kilcoyne, C.M.; Choucair, W.K.; Katz, A.; Quon, M.J.; Panza, J.A. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation, 1999, 100, 820-5.
65. Montagnani, M.; Ravichandran, L.V.; Chen, H.; Esposito, D.L.; Quon, M.J. Insulin receptor substrate-1 and phosphoinositidedependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol. Endocrinol., 2002, 16, 1931-42.
66. Kim, J.A.; Montagnani, M.; Koh, K.K.; Quon, M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation, 2006, 113, 1888-904.
67. Sheetz, M.J.; King, G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA, 2002, 288, 2579-88.
68. Mather, K.J.; Lteif, A.; Steinberg, H.O.; Baron, A.D. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes, 2004, 53, 2060-6.
69. Gimbrone, M.A., Jr. Vascular endothelium: An integrator of pathophysiologic stimuli in atherosclerosis. Am. J. Cardiol., 1995, 75, 67B-70B.
70. Wilcox, J.N.; Subramanian, R.R.; Sundell, C.L.; Tracey, W.R.; Pollock, J.S.; Harrison, D.G.; Marsden, P.A. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 2479-88.
71. Cosentino, F.; Patton, S.; d'Uscio, L.V.; Werner, E.R.; Werner-Felmayer, G.; Moreau, P.; Malinski, T.; Luscher, T.F. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J. Clin. Invest., 1998, 101, 1530-7.
72. Landmesser, U.; Dikalov, S.; Price, S.R.; McCann, L.; Fukai, T.; Holland, S.M.; Mitch, W.E.; Harrison, D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest., 2003, 111, 1201-9.
73. Koppenol, W.H.; Moreno, J.J.; Pryor, W.A.; Ischiropoulos, H.; Beckman, J.S. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem. Res. Toxicol., 1992, 5, 834-42
74. King, G.L. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes. Ann. Med., 1996, 28, 427-32.
75. Taylor, P.D.; Poston, L. The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery. Br. J. Pharmacol., 1994, 113, 801-8.
76. Lash, J.M.; Nase, G.P.; Bohlen, H.G. Acute hyperglycemia depresses arteriolar NO formation in skeletal muscle. Am. J. Physiol., 1999, 277, H1513-20.
77. Williams, S.B.; Goldfine, A.B.; Timimi, F.K.; Ting, H.H.; Roddy, M.A.; Simonson, D.C.; Creager, M.A. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation, 1998, 97, 1695-701.
78. Inoguchi, T.; Li, P.; Umeda, F.; Yu, H.Y.; Kakimoto, M.; Imamura, M.; Aoki, T.; Etoh, T.; Hashimoto, T.; Naruse, M.; Sano, H.; Utsumi, H.; Nawata, H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 2000, 49, 1939-45.
79. Milstien, S.; Katusic, Z. Oxidation of tetrahydrobiopterin by peroxynitrite: Implications for vascular endothelial function. Biochem. Biophys. Res. Commun., 1999, 263, 681-4.
80. Vasquez-Vivar, J.; Kalyanaraman, B.; Martasek, P.; Hogg, N.; Masters, B.S.; Karoui, H.; Tordo, P.; Pritchard, K.A., Jr. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 9220-5
81. Xia, Y.; Tsai, A.L.; Berka, V.; Zweier, J.L. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J. Biol. Chem., 1998, 273, 25804-8.
82. Heitzer, T.; Krohn, K.; Albers, S.; Meinertz, T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia, 2000, 43, 1435-8.
83. Lin, K.Y.; Ito, A.; Asagami, T.; Tsao, P.S.; Adimoolam, S.; Kimoto, M.; Tsuji, H.; Reaven, G.M.; Cooke, J.P. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation, 2002, 106, 987-92.
84. Potashnik, R.; Bloch-Damti, A.; Bashan, N.; Rudich, A. IRS1 degradation and increased serine phosphorylation cannot predict the degree of metabolic insulin resistance induced by oxidative stress. Diabetologia, 2003, 46, 639-48.
85. Guzik, T.J.; Mussa, S.; Gastaldi, D.; Sadowski, J.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation, 2002, 105, 1656-62.
86. Xia, P.; Inoguchi, T.; Kern, T.S.; Engerman, R.L.; Oates, P.J.; King, G.L. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes, 1994, 43, 1122-9.
87. Inoguchi, T.; Xia, P.; Kunisaki, M.; Higashi, S.; Feener, E.P.; King, G.L. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am. J. Physiol., 1994, 267, E369-79.
88. Tesfamariam, B.; Brown, M.L.; Cohen, R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest., 1991, 87, 1643-8.
89. Shiba, T.; Inoguchi, T.; Sportsman, J.R.; Heath, W.F.; Bursell, S.; King, G.L. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol., 1993, 265, E783-93.
90. Craven, P.A.; Davidson, C.M.; DeRubertis, F.R. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes, 1990, 39, 667-74.
91. Brownlee, M.; Cerami, A.; Vlassara, H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 1988, 318, 1315-21.
92. Hamada, Y.; Araki, N.; Koh, N.; Nakamura, J.; Horiuchi, S.; Hotta, N. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem. Biophys. Res. Commun., 1996, 228, 539-43.
93. Schmidt, A.M.; Yan, S.D.; Wautier, J.L.; Stern, D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res., 1999, 84, 489-97.
94. Wautier, M.P.; Chappey, O.; Corda, S.; Stern, D.M.; Schmidt, A.M.; Wautier, J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab., 2001, 280, E685-94.
95. Chavakis, T.; Bierhaus, A.; Nawroth, P.P. RAGE (receptor for advanced glycation end products): A central player in the inflammatory response. Microbes Infect., 2004, 6, 1219-25.
96. Xu, B.; Chibber, R.; Ruggiero, D.; Kohner, E.; Ritter, J.; Ferro, A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J., 2003, 17, 1289-91.
97. Chakravarthy, U.; Hayes, R.G.; Stitt, A.W.; McAuley, E.; Archer, D.B. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes, 1998, 47, 945-52.
98. Quehenberger, P.; Bierhaus, A.; Fasching, P.; Muellner, C.; Klevesath, M.; Hong, M.; Stier, G.; Sattler, M.; Schleicher, E.; Speiser, W.; Nawroth, P.P. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes, 2000, 49, 1561-70.
99. Gabriely, I.; Yang, X.M.; Cases, J.A.; Ma, X.H.; Rossetti, L.; Barzilai, N. Hyperglycemia modulates angiotensinogen gene expression. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 281, R795-802.
100. Nickenig, G.; Harrison, D.G. The AT(1)-type angiotensin receptor in oxOdative stress and atherogenesis: Part I: oxidative stress and atherogenesis. Circulation, 2002, 105, 393-6.
101. Collier, B.; Dossett, L.A.; May, A.K.; Diaz, J.J. Glucose control and the inflammatory response. Nutr. Clin. Pract., 2008, 23, 3-15.
102. Kelley, D.E.; Simoneau, J.A. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J. Clin. Invest., 1994, 94, 2349-56.
103. Steinberg, H.O.; Baron, A.D. Vascular function, insulin resistance and fatty acids. Diabetologia, 2002, 45, 623-34.
104. Steinberg, H.O.; Paradisi, G.; Hook, G.; Crowder, K.; Cronin, J.; Baron, A.D. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes, 2000, 49, 1231-8.
105. Tripathy, D.; Mohanty, P.; Dhindsa, S.; Syed, T.; Ghanim, H.; Aljada, A.; Dandona, P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes, 2003, 52, 2882-7.
106. Wang, X.L.; Zhang, L.; Youker, K.; Zhang, M.X.; Wang, J.; Le-Maire, S.A.; Coselli, J.S.; Shen, Y.H. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes, 2006, 55, 2301-10.
107. Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 2005, 54, 1615-25.
108. O'Donnell, V.B.; Freeman, B.A. Interactions between nitric oxide and lipid oxidation pathways: Implications for vascular disease. Circ. Res., 2001, 88, 12-21.
109. Lee, K.U.; Lee, I.K.; Han, J.; Song, D.K.; Kim, Y.M.; Song, H.S.; Kim, H.S.; Lee, W.J.; Koh, E.H.; Song, K.H.; Han, S.M.; Kim, M.S.; Park, I.S.; Park, J.Y. Effects of recombinant adenovirus-mediated uncoupling protein 2 overexpression on endothelial function and apoptosis. Circ. Res., 2005, 96, 1200-7.
110. Boden, G.; She, P.; Mozzoli, M.; Cheung, P.; Gumireddy, K.; Reddy, P.; Xiang, X.; Luo, Z.; Ruderman, N. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes, 2005, 54, 3458-65
111. Jove, M.; Planavila, A.; Sanchez, R.M.; Merlos, M.; Laguna, J.C.; Vazquez-Carrera, M. Palmitate induces tumor necrosis factor-alpha expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-kappaB activation. Endocrinology, 2006, 147, 552-61.
112. Gao, Z.; Zhang, X.; Zuberi, A.; Hwang, D.; Quon, M.J.; Lefevre, M.; Ye, J. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol. Endocrinol., 2004, 18, 2024-34.
113. Kim, F.; Tysseling, K.A.; Rice, J.; Pham, M.; Haji, L.; Gallis, B.M.; Baas, A.S.; Paramsothy, P.; Giachelli, C.M.; Corson, M.A.; Raines, E.W. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 989-94.
114. Naruse, K.; Rask-Madsen, C.; Takahara, N.; Ha, S.W.; Suzuma, K.; Way, K.J.; Jacobs, J.R.; Clermont, A.C.; Ueki, K.; Ohshiro, Y.; Zhang, J.; Goldfine, A.B.; King, G.L. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes, 2006, 55, 691-8.
115. Reaven, G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988, 37, 1595-607.
116. Nystrom, F.H.; Quon, M.J. Insulin signalling: Metabolic pathways and mechanisms for specificity. Cell Signal., 1999, 11, 563-74.
117. Federici, M.; Pandolfi, A.; De Filippis, E.A.; Pellegrini, G.; Menghini, R.; Lauro, D.; Cardellini, M.; Romano, M.; Sesti, G.; Lauro, R.; Consoli, A. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation, 2004, 109, 399-405.
118. Abe, H.; Yamada, N.; Kamata, K.; Kuwaki, T.; Shimada, M.; Osuga, J.; Shionoiri, F.; Yahagi, N.; Kadowaki, T.; Tamemoto, H.; Ishibashi, S.; Yazaki, Y.; Makuuchi, M. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J. Clin. Invest., 1998, 101, 1784-8.
119. Itani, S.I.; Ruderman, N.B.; Schmieder, F.; Boden, G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes, 2002, 51, 2005-11.
120. Ozcan, U.; Cao, Q.; Yilmaz, E.; Lee, A.H.; Iwakoshi, N.N.; Ozdelen, E.; Tuncman, G.; Gorgun, C.; Glimcher, L.H.; Hotamisligil, G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science, 2004, 306, 457-61.
121. Lum, H.; Roebuck, K.A. Oxidant stress and endothelial cell dysfunction. Am. J. Physiol. Cell Physiol., 2001, 280, C719-41.
122. Jiang, Z.Y.; Lin, Y.W.; Clemont, A.; Feener, E.P.; Hein, K.D.; Igarashi, M.; Yamauchi, T.; White, M.F.; King, G.L. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/ fa) rats. J. Clin. Invest., 1999, 104, 447-57.
123. Cusi, K.; Maezono, K.; Osman, A.; Pendergrass, M.; Patti, M.E.; Pratipanawatr, T.; DeFronzo, R.A.; Kahn, C.R.; Mandarino, L.J. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest., 2000, 105, 311-20.
124. Piatti, P.M.; Monti, L.D.; Conti, M.; Baruffaldi, L.; Galli, L.; Phan, C.V.; Guazzini, B.; Pontiroli, A.E.; Pozza, G. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes, 1996, 45, 316-21.
125. Arcaro, G.; Cretti, A.; Balzano, S.; Lechi, A.; Muggeo, M.; Bonora, E.; Bonadonna, R.C. Insulin causes endothelial dysfunction in humans: Sites and mechanisms. Circulation, 2002, 105, 576-82
126. Khan, Z.A.; Chakrabarti, S. Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp. Diabetes Res., 2007, 2007, 69527.
127. Aiello, L.P.; Bursell, S.E.; Clermont, A.; Duh, E.; Ishii, H.; Takagi, C.; Mori, F.; Ciulla, T.A.; Ways, K.; Jirousek, M.; Smith, L.E.; King, G.L. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes, 1997, 46, 1473-80.
128. Arita, R.; Hata, Y.; Nakao, S.; Kita, T.; Miura, M.; Kawahara, S.; Zandi, S.; Almulki, L.; Tayyari, F.; Shimokawa, H.; Hafezi-Moghadam, A.; Ishibashi, T. ROCK Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular Damage. Diabetes, 2008.
129. Schmidt, A.M.; Crandall, J.; Hori, O.; Cao, R.; Lakatta, E. Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: A marker of vascular dysfunction and progressive vascular disease. Br. J. Haematol., 1996, 92, 747-50.
130. Schalkwijk, C.G.; Poland, D.C.; van Dijk, W.; Kok, A.; Emeis, J.J.; Drager, A.M.; Doni, A.; van Hinsbergh, V.W.; Stehouwer, C.D. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: Evidence for chronic inflammation. Diabetologia, 1999, 42, 351-7.
131. Stehouwer, C.D.; Fischer, H.R.; van Kuijk, A.W.; Polak, B.C.; Donker, A.J. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes, 1995, 44, 561-4.
132. Stehouwer, C.D.; Gall, M.A.; Twisk, J.W.; Knudsen, E.; Emeis, J.J.; Parving, H.H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes, 2002, 51, 1157-65.
133. Satchell, S.C.; Tooke, J.E. What is the mechanism of microalbuminuria in diabetes: A role for the glomerular endothelium? Diabetologia, 2008, 51, 714-25.
134. Parving, H.H.; Hovind, P. Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr. Hypertens Rep., 2002, 4, 387-93.
135. Ludmer, P.L.; Selwyn, A.P.; Shook, T.L.; Wayne, R.R.; Mudge, G.H.; Alexander, R.W.; Ganz, P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med., 1986, 315, 1046-51.
136. Sonoki, K.; Yoshinari, M.; Iwase, M.; Iino, K.; Ichikawa, K.; Ohdo, S.; Higuchi, S.; Iida, M. Glycoxidized low-density lipoprotein enhances monocyte chemoattractant protein-1 mRNA expression in human umbilical vein endothelial cells: Relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism, 2002, 51, 1135-42.
137. Pandolfi, A.; De Filippis, E.A. Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications. Genes Nutr., 2007, 2, 195-208.
138. Rask-Madsen, C.; King, G.L. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 487-96.
139. Quagliaro, L.; Piconi, L.; Assaloni, R.; Da Ros, R.; Maier, A.; Zuodar, G.; Ceriello, A. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: The distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis, 2005, 183, 259-67.
140. Nathan, D.M.; Cleary, P.A.; Backlund, J.Y.; Genuth, S.M.; Lachin, J.M.; Orchard, T.J.; Raskin, P.; Zinman, B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med., 2005, 353, 2643-53.
141. Franklin, V.L.; Khan, F.; Kennedy, G.; Belch, J.J.; Greene, S.A. Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes. Diabetologia, 2008, 51, 353-60.
142. Vehkavaara, S.; Makimattila, S.; Schlenzka, A.; Vakkilainen, J.; Westerbacka, J.; Yki-Jarvinen, H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 545-50.
143. Vehkavaara, S.; Yki-Jarvinen, H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 325-30.
144. Antoniades, C.; Tousoulis, D.; Marinou, K.; Papageorgiou, N.; Bosinakou, E.; Tsioufis, C.; Stefanadi, E.; Latsios, G.; Tentolouris, C.; Siasos, G.; Stefanadis, C. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clin. Cardiol., 2007, 30, 295-300.
145. Hamilton, S.J.; Chew, G.T.; Watts, G.F. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diabetes Vasc. Dis. Res., 2007, 4, 89-102.
146. Bishop-Bailey, D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol., 2000, 129, 823-34.
147. Loviscach, M.; Rehman, N.; Carter, L.; Mudaliar, S.; Mohadeen, P.; Ciaraldi, T.P.; Veerkamp, J.H.; Henry, R.R. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action. Diabetologia, 2000, 43, 304-11.
148. Olefsky, J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J. Clin. Invest., 2000, 106, 467-72.
149. Hauner, H. The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev., 2002, 18 Suppl 2, S10-5.
150. Saltiel, A.R.; Olefsky, J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 1996, 45, 1661-9.
151. Freed, M.I.; Ratner, R.; Marcovina, S.M.; Kreider, M.M.; Biswas, N.; Cohen, B.R.; Brunzell, J.D. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol., 2002, 90, 947-52.
152. Dandona, P.; Aljada, A. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. J. Diabetes Compl., 2004, 18, 91-102.
153. Fujishima, S.; Ohya, Y.; Nakamura, Y.; Onaka, U.; Abe, I.; Fujishima, M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am. J. Hypertens., 1998, 11, 1134-7.
154. Kim, Y.B.; Ciaraldi, T.P.; Kong, A.; Kim, D.; Chu, N.; Mohideen, P.; Mudaliar, S.; Henry, R.R.; Kahn, B.B. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes, 2002, 51, 443-8.
155. Formoso, G.; Chen, H.; Kim, J.A.; Montagnani, M.; Consoli, A.; Quon, M.J. Dehydroepiandrosterone Mimics Acute Actions of Insulin to Stimulate Production of Both Nitric Oxide and Endothelin 1 via Distinct
156. Stuhlinger, M.C.; Abbasi, F.; Chu, J.W.; Lamendola, C.; McLaughlin, T.L.; Cooke, J.P.; Reaven, G.M.; Tsao, P.S. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 2002, 287, 1420-6.
157. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998, 391, 79-82.
158. Jiang, C.; Ting, A.T.; Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391, 82-6.
159. Bagi, Z.; Koller, A.; Kaley, G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol, 2004, 286, H742-8.
160. Ceolotto, G.; Gallo, A.; Papparella, I.; Franco, L.; Murphy, E.; Iori, E.; Pagnin, E.; Fadini, G.P.; Albiero, M.; Semplicini, A.; Avogaro, A. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2627-33.
161. Wakino, S.; Law, R.E.; Hsueh, W.A. Vascular protective effects by activation of nuclear receptor PPARgamma. J. Diabetes Complications, 2002, 16, 46-9.
162. Haffner, S.M.; Greenberg, A.S.; Weston, W.M.; Chen, H.; Williams, K.; Freed, M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002, 106, 679-84.
163. Sidhu, J.S.; Kaposzta, Z.; Markus, H.S.; Kaski, J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 930-4
164. Bailey, C.J. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes. Metab., 2005, 7, 675-91.
165. Raji, A.; Seely, E.W.; Bekins, S.A.; Williams, G.H.; Simonson, D.C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care, 2003, 26, 172-8.
166. Guan, Y.; Hao, C.; Cha, D.R.; Rao, R.; Lu, W.; Kohan, D.E.; Magnuson, M.A.; Redha, R.; Zhang, Y.; Breyer, M.D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med., 2005, 11, 861-6.
167. Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Lefebvre, P.J.; Murray, G.D.; Standl, E.; Wilcox, R.G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R.J.; Koranyi, L.; Laakso, M.; Mokan, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet, 2005, 366, 1279-89.
168. Home, P.D.; Pocock, S.J.; Beck-Nielsen, H.; Gomis, R.; Hanefeld, M.; Dargie, H.; Komajda, M.; Gubb, J.; Biswas, N.; Jones, N.P. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia, 2005, 48, 1726-35.
169. Gerstein, H.C.; Yusuf, S.; Bosch, J.; Pogue, J.; Sheridan, P.; Dinccag, N.; Hanefeld, M.; Hoogwerf, B.; Laakso, M.; Mohan, V.; Shaw, J.; Zinman, B.; Holman, R.R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet, 2006, 368, 1096-105.
170. Marx, N.; Duez, H.; Fruchart, J.C.; Staels, B. Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ. Res., 2004, 94, 1168-78.
171. Goya, K.; Sumitani, S.; Xu, X.; Kitamura, T.; Yamamoto, H.; Kurebayashi, S.; Saito, H.; Kouhara, H.; Kasayama, S.; Kawase, I. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 658-63.
172. Irukayama-Tomobe, Y.; Miyauchi, T.; Kasuya, Y.; Sakai, S.; Goto, K.; Yamaguchi, I. Activation of Peroxisome Proliferator-activated Receptor-alpha Decreases Endothelin-1-induced p38 Mitogen-activated Protein Kinase Activation in Cardiomyocytes. J. Cardiovasc. Pharmacol., 2004, 44, S358-S61.
173. Irukayama-Tomobe, Y.; Miyauchi, T.; Sakai, S.; Kasuya, Y.; Ogata, T.; Takanashi, M.; Iemitsu, M.; Sudo, T.; Goto, K.; Yamaguchi, I. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation, 2004, 109, 904-10.
174. Israelian-Konaraki, Z.; Reaven, P.D. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: From basic mechanisms to clinical implications. Cardiol. Rev., 2005, 13, 240-6.
175. Koh, K.K.; Han, S.H.; Quon, M.J.; Yeal Ahn, J.; Shin, E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care, 2005, 28, 1419-24.
176. Koh, K.K.; Quon, M.J.; Han, S.H.; Chung, W.J.; Ahn, J.Y.; Kim, J.A.; Lee, Y.; Shin, E.K. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care, 2006, 29, 195-201.
177. Avogaro, A.; Miola, M.; Favaro, A.; Gottardo, L.; Pacini, G.; Manzato, E.; Zambon, S.; Sacerdoti, D.; de Kreutzenberg, S.; Piliego, T.; Tiengo, A.; Del Prato, S. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur. J. Clin. Invest., 2001, 31, 603-9.
178. Keech, A.; Simes, R.J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M.R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; Drury, P.; Kesaniemi, Y.A.; Sullivan, D.; Hunt, D.; Colman, P.; d'Emden, M.; Whiting, M.; Ehnholm, C.; Laakso, M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet, 2005, 366, 1849-61.
179. Kureishi, Y.; Luo, Z.; Shiojima, I.; Bialik, A.; Fulton, D.; Lefer, D.J.; Sessa, W.C.; Walsh, K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med., 2000, 6, 1004-10.
180. Takemoto, M.; Liao, J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1712-9
181. Laufs, U.; Liao, J.K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc. Med., 2000, 10, 143-8.
182. Paniagua, J.A.; Lopez-Miranda, J.; Escribano, A.; Berral, F.J.; Marin, C.; Bravo, D.; Paz-Rojas, E.; Gomez, P.; Barcos, M.; Moreno, J.A.; Perez-Jimenez, F. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes, 2002, 51, 2596-603.
183. Economides, P.A.; Caselli, A.; Tiani, E.; Khaodhiar, L.; Horton, E.S.; Veves, A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J. Clin. Endocrinol. Metab., 2004, 89, 740-7.
184. Wassmann, S.; Laufs, U.; Muller, K.; Konkol, C.; Ahlbory, K.; Baumer, A.T.; Linz, W.; Bohm, M.; Nickenig, G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 300-5.
185. Ceriello, A.; Quagliaro, L.; Piconi, L.; Assaloni, R.; Da Ros, R.; Maier, A.; Esposito, K.; Giugliano, D. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes, 2004, 53, 701-10.
186. Ceriello, A.; Quagliaro, L.; Catone, B.; Pascon, R.; Piazzola, M.; Bais, B.; Marra, G.; Tonutti, L.; Taboga, C.; Motz, E. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care, 2002, 25, 1439-43.
187. Sowers, J.R. Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am. J. Cardiol., 2003, 91, 14B-22B.
188. Goldberg, R.B.; Mellies, M.J.; Sacks, F.M.; Moye, L.A.; Howard, B.V.; Howard, W.J.; Davis, B.R.; Cole, T.G.; Pfeffer, M.A.; Braunwald, E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation, 1998, 98, 2513-9.
189. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 2002, 360, 7-22.
190. Koh, K.K.; Chung, W.J.; Ahn, J.Y.; Han, S.H.; Kang, W.C.; Seo, Y.H.; Ahn, T.H.; Choi, I.S.; Shin, E.K. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: A randomized, double-blind, placebo-controlled study. Atherosclerosis, 2004, 177, 155-60.
191. Koh, K.K.; Quon, M.J.; Han, S.H.; Ahn, J.Y.; Jin, D.K.; Kim, H.S.; Kim, D.S.; Shin, E.K. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension, 2005, 45, 1088-93.
192. Folli, F.; Kahn, C.R.; Hansen, H.; Bouchie, J.L.; Feener, E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J. Clin. Invest., 1997, 100, 2158-69.
193. Abuissa, H.; Jones, P.G.; Marso, S.P.; O'Keefe, J.H., Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol., 2005, 46, 821-6.
194. Schupp, M.; Janke, J.; Clasen, R.; Unger, T.; Kintscher, U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation, 2004, 109, 2054-7.
195. Rueckschloss, U.; Quinn, M.T.; Holtz, J.; Morawietz, H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: Protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1845-51.
196. Hermann, T.S.; Li, W.; Dominguez, H.; Ihlemann, N.; Rask-Madsen, C.; Major-Pedersen, A.; Nielsen, D.B.; Hansen, K.W.; Hawkins, M.; Kober, L.; Torp-Pedersen, C. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2006, 91, 1001-8.
197. Furuhashi, M.; Ura, N.; Higashiura, K.; Murakami, H.; Tanaka, M.; Moniwa, N.; Yoshida, D.; Shimamoto, K. Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension. Hypertension, 2003, 42, 71-81.
198. Bosch, J.; Yusuf, S.; Gerstein, H.C.; Pogue, J.; Sheridan, P.; Dagenais, G.; Diaz, R.; Avezum, A.; Lanas, F.; Probstfield, J.; Fodor, G.; Holman, R.R. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med., 2006, 355, 1551-62.
199. Lewis, E.J.; Hunsicker, L.G.; Clarke, W.R.; Berl, T.; Pohl, M.A.; Lewis, J.B.; Ritz, E.; Atkins, R.C.; Rohde, R.; Raz, I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345, 851-60.
200. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001, 345, 861-9.
201. Parving, H.H.; Lehnert, H.; Brochner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med., 2001, 345, 870-8.
202. Brownlee, M.; Vlassara, H.; Kooney, A.; Ulrich, P.; Cerami, A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science, 1986, 232, 1629-32.
203. Bolton, W.K.; Cattran, D.C.; Williams, M.E.; Adler, S.G.; Appel, G.B.; Cartwright, K.; Foiles, P.G.; Freedman, B.I.; Raskin, P.; Ratner, R.E.; Spinowitz, B.S.; Whittier, F.C.; Wuerth, J.P. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol., 2004, 24, 32-40.
204. Freedman, B.I.; Wuerth, J.P.; Cartwright, K.; Bain, R.P.; Dippe, S.; Hershon, K.; Mooradian, A.D.; Spinowitz, B.S. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin. Trials, 1999, 20, 493-510.
205. Montagnani, M. Diabetic cardiomyopathy: How much does it depend on AGE? Br. J. Pharmacol., 2008, 154, 725-6.
206. Voziyan, P.A.; Hudson, B.G. Pyridoxamine: The many virtues of a maillard reaction inhibitor. Ann. N. Y. Acad. Sci., 2005, 1043, 807-16.
207. Stirban, A.; Negrean, M.; Stratmann, B.; Gawlowski, T.; Horstmann, T.; Gotting, C.; Kleesiek, K.; Mueller-Roesel, M.; Koschinsky, T.; Uribarri, J.; Vlassara, H.; Tschoepe, D. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care, 2006, 29, 2064-71.
208. Kass, D.A.; Shapiro, E.P.; Kawaguchi, M.; Capriotti, A.R.; Scuteri, A.; deGroof, R.C.; Lakatta, E.G. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation, 2001, 104, 1464-70.
209. Little, W.C.; Zile, M.R.; Kitzman, D.W.; Hundley, W.G.; O'Brien, T.X.; Degroof, R.C. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J. Card. Fail, 2005, 11, 191-5.
210. Beckman, J.A.; Goldfine, A.B.; Gordon, M.B.; Garrett, L.A.; Creager, M.A. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ. Res., 2002, 90, 107-11.
211. Campochiaro, P.A. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci., 2004, 45, 922-31.
212. Strom, C.; Sander, B.; Klemp, K.; Aiello, L.P.; Lund-Andersen, H.; Larsen, M. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest. Ophthalmol. Vis. Sci., 2005, 46, 3855-8.
213. Aiello, L.P.; Clermont, A.; Arora, V.; Davis, M.D.; Sheetz, M.J.; Bursell, S.E. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci., 2006, 47, 86-92.
214. Vinik, A.I.; Bril, V.; Kempler, P.; Litchy, W.J.; Tesfaye, S.; Price, K.L.; Bastyr, E.J., 3rd. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin. Ther., 2005, 27, 1164-80
215. Shen, H.; Clauss, M.; Ryan, J.; Schmidt, A.M.; Tijburg, P.; Borden, L.; Connolly, D.; Stern, D.; Kao, J. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood, 1993, 81, 2767-73
216. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev., 2004, 25, 581-611.
217. van Wijngaarden, P.; Coster, D.J.; Williams, K.A. Inhibitors of ocular neovascularization: Promises and potential problems. JAMA, 2005, 293, 1509-13.
218. Cunningham, E.T., Jr.; Adamis, A.P.; Altaweel, M.; Aiello, L.P.; Bressler, N.M.; D'Amico, D.J.; Goldbaum, M.; Guyer, D.R.; Katz, B.; Patel, M.; Schwartz, S.D. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology, 2005, 112, 1747-57.
219. Heier, J.S.; Antoszyk, A.N.; Pavan, P.R.; Leff, S.R.; Rosenfeld, P.J.; Ciulla, T.A.; Dreyer, R.F.; Gentile, R.C.; Sy, J.P.; Hantsbarger, G.; Shams, N. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology, 2006, 113, 633 e1-4.
220. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350, 2335-42.
221. Rich, R.M.; Rosenfeld, P.J.; Puliafito, C.A.; Dubovy, S.R.; Davis, J.L.; Flynn, H.W., Jr.; Gonzalez, S.; Feuer, W.J.; Lin, R.C.; Lalwani, G.A.; Nguyen, J.K.; Kumar, G. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina, 2006, 26, 495-511.
222. Mason, J.O., 3rd; Nixon, P.A.; White, M.F. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am. J. Ophthalmol., 2006, 142, 685-8
223. Isaacs, T.W.; Barry, C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin. Exp. Ophthalmol., 2006, 34, 802-3.
224. Avery, R.L.; Pearlman, J.; Pieramici, D.J.; Rabena, M.D.; Castellarin, A.A.; Nasir, M.A.; Giust, M.J.; Wendel, R.; Patel, A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology, 2006, 113, 1695 e1-15.
225. Friedlander, S.M.; Welch, R.M. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch Ophthalmol, 2006, 124, 1365.
226. Chen, E.; Park, C.H. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina, 2006, 26, 699-700
227. Steinbrook, R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N. Engl. J. Med., 2006, 355, 1409-12.
228. Jorge, R.; Costa, R.A.; Calucci, D.; Cintra, L.P.; Scott, I.U. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina, 2006, 26, 1006-13.
229. Touyz, R.M. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance? Hypertension, 2004, 44, 248-52.
230. Anderson, R.A.; Evans, L.M.; Ellis, G.R.; Khan, N.; Morris, K.; Jackson, S.K.; Rees, A.; Lewis, M.J.; Frenneaux, M.P. Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type 2 diabetes. Diabet. Med., 2006, 23, 258-64.
231. Antoniades, C.; Tousoulis, D.; Tountas, C.; Tentolouris, C.; Toutouza, M.; Vasiliadou, C.; Tsioufis, C.; Toutouzas, P.; Stefanadis, C. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: The effects of vitamin C. Diabet. Med., 2004, 21, 552-8.
232. Paolisso, G.; Tagliamonte, M.R.; Barbieri, M.; Zito, G.A.; Gambardella, A.; Varricchio, G.; Ragno, E.; Varricchio, M. Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients. J. Clin. Endocrinol. Metab., 2000, 85, 109-15.
233. Darko, D.; Dornhorst, A.; Kelly, F.J.; Ritter, J.M.; Chowienczyk, P.J. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. Clin Sci (Lond), 2002, 103, 339-44.
234. Stephens, N.G.; Parsons, A.; Schofield, P.M.; Kelly, F.; Cheeseman, K.; Mitchinson, M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet, 1996, 347, 781-6.
235. Virtamo, J.; Rapola, J.M.; Ripatti, S.; Heinonen, O.P.; Taylor, P.R.; Albanes, D.; Huttunen, J.K. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch. Intern. Med., 1998, 158, 668-75.
236. Lee, D.H.; Folsom, A.R.; Harnack, L.; Halliwell, B.; Jacobs, D.R., Jr. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am. J. Clin. Nutr., 2004, 80, 1194-200.
237. Lonn, E.; Bosch, J.; Yusuf, S.; Sheridan, P.; Pogue, J.; Arnold, J.M.; Ross, C.; Arnold, A.; Sleight, P.; Probstfield, J.; Dagenais, G.R. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA, 2005, 293, 1338-47.
238. Miller, E.R., 3rd; Pastor-Barriuso, R.; Dalal, D.; Riemersma, R.A.; Appel, L.J.; Guallar, E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med., 2005, 142, 37-46.
239. Heitzer, T.; Finckh, B.; Albers, S.; Krohn, K.; Kohlschutter, A.; Meinertz, T. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: Relation to parameters of oxidative stress. Free Radic. Biol. Med., 2001, 31, 53-61.
240. Sola, S.; Mir, M.Q.; Cheema, F.A.; Khan-Merchant, N.; Menon, R.G.; Parthasarathy, S.; Khan, B.V. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation, 2005, 111, 343-8.
241. Hodgson, J.M.; Watts, G.F.; Playford, D.A.; Burke, V.; Croft, K.D. Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes. Eur. J. Clin. Nutr., 2002, 56, 1137-42.
242. Watts, G.F.; Playford, D.A.; Croft, K.D.; Ward, N.C.; Mori, T.A.; Burke, V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia, 2002, 45, 420-6.
243. Playford, D.A.; Watts, G.F.; Croft, K.D.; Burke, V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis, 2003, 168, 169-79.
244. Wiltshire, E.J.; Gent, R.; Hirte, C.; Pena, A.; Thomas, D.W.; Couper, J.J. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. Diabetes, 2002, 51, 2282-6.
245. Pena, A.S.; Wiltshire, E.; Gent, R.; Hirte, C.; Couper, J. Folic acid improves endothelial function in children and adolescents with type 1 diabetes. J. Pediatr., 2004, 144, 500-4.
246. Mangoni, A.A.; Sherwood, R.A.; Asonganyi, B.; Swift, C.G.; Thomas, S.; Jackson, S.H. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am. J. Hypertens, 2005, 18, 220-6.
247. Title, L.M.; Ur, E.; Giddens, K.; McQueen, M.J.; Nassar, B.A. Folic acid improves endothelial dysfunction in type 2 diabetes - an effect independent of homocysteine-lowering. Vasc. Med., 2006, 11, 101-9.
248. Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. J. Nutr., 2000, 130, 2073S-85S.
249. Maxwell, S.; Cruickshank, A.; Thorpe, G. Red wine and antioxidant activity in serum. Lancet, 1994, 344, 193-4.
250. Stolk, J.; Hiltermann, T.J.; Dijkman, J.H.; Verhoeven, A.J. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am. J. Respir. Cell Mol. Biol., 1994, 11, 95-102.
251. Ghosh, M., Wang, H.D., and McNeill, J.R. Role of oxidative stress and nitric oxide in regulation of spontaneous tone in aorta of DOCA-salt hypertensive rats. Br. J. Pharmacol., 2004, 141, 562-73.
252. Diatchuk, V.; Lotan, O.; Koshkin, V.; Wikstroem, P.; Pick, E. Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J. Biol. Chem., 1997, 272, 13292-301.
253. Cayatte, A.J.; Rupin, A.; Oliver-Krasinski, J.; Maitland, K.; Sansilvestri-Morel, P.; Boussard, M.F.; Wierzbicki, M.; Verbeuren, T.J.; Cohen, R.A. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1577-84.
254. Rey, F.E.; Cifuentes, M.E.; Kiarash, A.; Quinn, M.T.; Pagano, P.J. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ. Res., 2001, 89, 408-14.
255. Jacobson, G.M.; Dourron, H.M.; Liu, J.; Carretero, O.A.; Reddy, D.J.; Andrzejewski, T.; Pagano, P.J. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ. Res., 2003, 92, 637-43
256. Ikeda, Y.; Young, L.H.; Scalia, R.; Ross, C.R.; Lefer, A.M. PR-39, a proline/arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia-reperfusion. Cardiovasc. Res., 2001, 49, 69-77.
257. Kern, T.S.; Engerman, R.L. Pharmacological inhibition of diabetic retinopathy: Aminoguanidine and aspirin. Diabetes, 2001, 50, 1636-42.
258. Zheng, L.; Howell, S.J.; Hatala, D.A.; Huang, K.; Kern, T.S. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes, 2007, 56, 337-45
259. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. Ophthalmology, 1991, 98, 757-65.
260. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes, 1989, 38, 491-8.
261. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J., 2002, 324(7329), 71-86.
262. Neri Serneri, G.G.; Coccheri, S.; Marubini, E.; Violi, F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study. Eur. Heart J., 2004, 25, 1845-52.
263. Celestini, A.; Violi, F. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc. Health Risk Manag., 2007, 3, 93-8.
264. Bilsborough, W.; O'Driscoll, G.; Stanton, K.; Weerasooriya, R.; Dembo, L.; Taylor, R.;Green, D. Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in Type II diabetes. Clin. Sci. (Lond.), 2002, 103, 163-9.
265. Cameron, N.E.;Cotter, M.A. Pro-inflammatory mechanisms in diabetic neuropathy: Focus on the nuclear factor kappa B pathway. Curr. Drug Targets, 2008, 9, 60-7.